Please login to the form below

Not currently logged in
Email:
Password:

Xolair

This page shows the latest Xolair news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals positive efficacy data for Xolair follow-up

Novartis reveals positive efficacy data for Xolair follow-up

The new treatment is being studied in chronic spontaneous urticaria (CSU), one of Xolair’s  approved indications. ... According to Novartis, ligelizumab binds to IgE with an 88-fold higher affinity than Xolair, with the two binding differently to the

Latest news

More from news
Approximately 10 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics